Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail.
Hayder M Al-KuraishyAli I Al-GareebEngy ElekhnawyGaber El-Saber BatihaPublished in: The Egyptian journal of medical human genetics (2022)
Our study concluded that DIP has a potential therapeutic effect in the management and treatment of Covid-19. This could be attained either directly, through anti-SARS-CoV-2, anti-inflammatory, and anti-platelets properties, or indirectly, through augmentation of extracellular adenosine, which has anti-inflammatory and immune-regulatory effects. However, extensive randomized clinical trials, and clinical and prospective research in this area are required to demonstrate the safety and therapeutic efficacy of DIP and adenosine modulators in the treatment of Covid-19.